Madrigal Pharmaceuticals Inc
Research Madrigal Pharmaceuticals Inc (MDGL) on Bullrun: market cap USD 11.83B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerMDGL
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 11.83B
- Financial periodQ2 2026
- RevenueUSD 364.25M
- Net income-USD 57.94M
- Free cash flowUSD 19.08M
- Gross margin89.0%
Valuation Snapshot
latest market cap is USD 11.83B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 958.40M | -USD 288.28M | -USD 190.02M | 94.1% | -10.15 | USD 198.69M | USD 339.88M | USD 602.69M |
| FY2024 | USD 180.13M | -USD 465.89M | -USD 457.03M | 96.5% | -17.31 | USD 100.02M | USD 117.57M | USD 754.38M |
| FY2023 | USD 0 | -USD 373.63M | -USD 325.71M | n/a | -17.33 | USD 99.92M | USD 115.48M | USD 405.33M |
| FY2022 | USD 0 | -USD 295.25M | -USD 225.07M | n/a | -17.23 | USD 331.55M | USD 49.29M | USD 197.39M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 11.83B | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 13.30B | n/a | n/a | n/a |
| 2024 | 2024-12-31 | USD 6.79B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 4.57B | n/a | n/a | n/a |
| 2022 | 2022-12-30 | USD 5.18B | n/a | n/a | n/a |
| 2021 | 2021-12-31 | USD 1.45B | n/a | n/a | n/a |
About Madrigal Pharmaceuticals Inc
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Madrigal Pharmaceuticals Inc's market cap?
Madrigal Pharmaceuticals Inc's market capitalization is USD 11.83B.
What does Madrigal Pharmaceuticals Inc do?
Madrigal Pharmaceuticals, Inc., a biopharmaceutical company, focuses on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH) in the United States. It offers Rezdiffra, a liver-directed thyroid hormone receptor beta agonist for treating MASH. The company was founded in 2016 and is headquartered in West Conshohocken, Pennsylvania.